Breaking News

Researchers used array-based DNA methylation data to quantify methylation levels in almost 1,500 identical or non-identical twins.

A heterozygous variant upstream of the BRCA1 translation start site was uncovered in all individuals in these two families with hypermethylated BRCA1 promoters.

Abbott confirmed that the move is a consequence of TwistDx evaluating its operations and strategic direction to align operations and commercial needs.

HTG Molecular Diagnostics offers next-generation sequencing-based molecular profiling instruments and assays, as well as related lab services.

Fluidigm reported that its mass cytometry revenues jumped 32 percent while genomics revenues fell 5 percent year over year.

Clinical research has shown that the assay exhibited 100 percent sensitivity compared to culture-based testing methods, Hologic said.

The firm said it saw strong reimbursement for the Oncotype DX Breast Recurrence test and increased private payor reimbursement for its Genomic Prostate test.

The firm's lab services and product revenues fell year over year, but collaboration revenues increased during Q2.

The company reported revenues of $443.7 million and organic growth of 3 percent, driven in large part by strength in its scientific instruments business.

PacBio's revenues increased to $21.6 million, but missed analysts average estimate of $23.8 million.

The researchers showed that Cas12a discriminates strongly against mismatches to DNA targets, leading to less off-target DNA cleavage than with Cas9.

Led by researchers at the University of Iceland, the study combined deep proteomic, genomic, and phenotypic data from a cohort of more than 5,000 subjects.

A Stony Brook University-led team re-analyzed the FOXP2 gene for signs of selection using a larger, more diverse cohort, but were unable to find any.

Diet- and height-related variants were selected for in a Flores Island pygmy population, according to a study, which also provided insights into the population's history.

The company's life sciences segment had $1.08 billion in revenues, driven by strong performance of the preanalytical systems, diagnostic systems, and biosciences units.

Revenue gains made by the company's protein and molecular diagnostics units were offset by weak demand for its Novaprep cytology products.

Revenues from the company's diagnostics business and discovery and analytical solutions business each grew 10 percent on an organic basis.

The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.

Exosome markets a urine-based test called ExoDx Prostate (IntelliScore) to help determine whether patients with ambiguous PSA tests needs a prostate biopsy.

The system, called EvolvR, can continuously diversify all nucleotides within a tunable window at user-defined loci using CRISPR-guided nickases.

Natera led the Index for the second month in a row after it announced that it intended to raise $75 million in a public stock offering.

The teams, from the Chinese Academy of Sciences and NYU Langone Health, generated viable yeast strains with just one or two chromosomes.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.